OSCR
Oscar Health, Inc.
OSCR has the edge over TELA overall, supported by stronger fundamentals and lower modeled downside.
TELA
TELA Bio, Inc.
TELA offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TELA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
TELA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TELA PE Valuation
TELA has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over TELA on the outlook, with more favorable revenue expectations.
TELA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TELA's losses to shrink, with revenue holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TELA on earnings quality, reporting a profit while its opponent remains loss making.
TELA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.74 | +$0.09 |
| Q2 2026 | -$0.77 | +$0.29 |
| Q1 2026 | -$0.79 | +$0.56 |
| Q4 2025 | -$0.83 | +$0.50 |
| Q3 2025 | -$0.83 | +$0.83 |
| Q2 2025 | -$1.06 | +$0.63 |
| Q1 2025 | -$1.35 | +$0.29 |
| Q4 2024 | -$1.33 | +$0.71 |
TELA is still losing money, but far less than before: $0.74 per share over the past year, against $2.87 at its worst in late 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TELA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over TELA on profitability, with a higher operating margin.
TELA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | -8.4% |
| Q2 2026 | $19.3M | -4.5% |
| Q1 2026 | $19.1M | +2.9% |
| Q4 2025 | $20.9M | +18% |
| Q3 2025 | $20.7M | +9.1% |
| Q2 2025 | $20.2M | +26% |
| Q1 2025 | $18.5M | +12% |
| Q4 2024 | $17.6M | +3.8% |
TELA's revenue has held roughly level: $19M last quarter, down 8.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -38% | -1.9 points |
| Q2 2026 | -48% | -3.2 points |
| Q1 2026 | -55% | +1.3 points |
| Q4 2025 | -32% | +16 points |
| Q3 2025 | -37% | +13 points |
| Q2 2025 | -45% | +27 points |
| Q1 2025 | -57% | -28 points |
| Q4 2024 | -47% | +25 points |
TELA's operating margin was −38% last quarter, down 1.9 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TELA on cash generation, producing positive trailing cash flow while its opponent burns cash.
TELA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.7M | -$2.8M |
| Q2 2026 | -$9.4M | -$1.4M |
| Q1 2026 | -$11.3M | -$1.5M |
| Q4 2025 | -$5M | +$2.8M |
| Q3 2025 | -$5.9M | +$3.2M |
| Q2 2025 | -$8M | +$3M |
| Q1 2025 | -$9.8M | +$4.9M |
| Q4 2024 | -$7.8M | +$3.5M |
TELA has burned cash in almost every quarter: −$34M over the past year, against −$32M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TELA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +275K shares |
| 1 year | +27% | +12.3M shares |
| 3 years | +148% | +34.4M shares |
| 5 years | +299% | +43.2M shares |
| Available history | +406% | +46.3M shares |
TELA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TELA Net Leverage
TELA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TELA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.7 | Neutral |
| Stochastic | 25.3 | Neutral |
TELA's weekly RSI is 48 (neutral) and its Stochastic is 25 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TELA PE vs Healthcare Sector
TELA has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TELA on trend strength, trading above more of its moving averages.
TELA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 13% below |
| 20 week MA | $0.88 | 2.3% below |
| 50 week MA | $0.88 | 2.3% below |
| 100 week MA | $1.34 | 36% below |
| 200 week MA | $4.07 | 79% below |
TELA is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TELA on returns for 2026, with the stronger performance.
TELA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.7 | $16.0 | +26% |
| 2021 | $16.0 | $12.5 | -22% |
| 2022 | $12.5 | $11.3 | -10% |
| 2023 | $11.3 | $6.62 | -41% |
| 2024 | $6.62 | $2.91 | -56% |
| 2025 | $2.91 | $1.14 | -61% |
| 2026 YTD | $1.14 | $0.86 | -25% |
TELA has finished five years in a row lower, and it's down 25% so far in 2026.